Wize Pharma merges with Australian Bitcoin miner Cosmos
The Israeli biopharmaceutical company will spin off its drug development activity and focus on Bitcoin mining.
Israeli clinical stage biopharmaceutical company Wize Pharma Inc. (OTCQB: WIZP) will merge with privately-held Australian digital currency infrastructure provider Cosmos Capital, in an all share deal, which will ultimately leave Cosmos s shareholders owning most of Wize s shares. Wize, which is controlled by Rimon Gold, the investment arm of serial entrepreneur Yair Goldfinger, US investor Jonathan Rubini, and its CEO Noam Danenberg, will spin off its ophthalmic disorders drug development activities.
Cosmos, which was founded 18 months ago, mainly specializes in mining Bitcoin as well as providing a digital infrastructure, which aims to act as a bridge between the growing digital currency industry and traditional capital markets. Mining Bitcoin is a process of verifying transactions in digital currencies through the
Wize Pharma and Cosmos Capital enter into Bid Implementation Agreement
USA - English
- Cosmos Capital, a digital infrastructure provider, to become publicly traded through a business combination with Wize
- The combined company is expected to have approximately US$5 million in cash and cash equivalents at closing
News provided by
Share this article
HOD HASHARON, Israel, and SYDNEY, Dec. 30, 2020 /PRNewswire/
Wize Pharma, Inc. (OTCQB: WIZP), a clinical-stage biopharmaceutical company focused on the treatment of ophthalmic disorders, and Cosmos Capital Limited, a leading digital infrastructure provider based in Sydney, Australia, today announced that they have entered into a bid implementation agreement ( BIA ), whereby Wize has agreed to make an off-market takeover offer to acquire all of the outstanding shares of Cosmos, subject to satisfaction of various closing conditions set forth in the BIA, resulting in Cosmos becoming a wholly-owned subsidiary of Wize.